All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Atezolizumab Monotherapy Falls Short in Exploratory OS Analysis in Untreated Locally Advanced or Metastatic Urothelial Cancer

February 18th 2023

Atezolizumab monotherapy failed to show an improvement in overall survival compared with placebo plus platinum-based chemotherapy and gemcitabine in patients with untreated locally advanced or metastatic urothelial cancer.

Pembrolizumab Produces High DFS Rates in BCG-unresponsive NMIBC

February 18th 2023

Pembrolizumab monotherapy led notable antitumor activity with manageable toxicity in patients with Bacillus Calmette-Guérin–unresponsive, papillary high-risk non–muscle-invasive bladder cancer

Rucaparib Bests Physician's Choice for BRCA+ mCRPC

February 17th 2023

The PARP inhibitor rucaparib improved median radiographic progression-free survival by 4.8 months compared with physician’s choice of therapy for men with BRCA-altered metastatic castration-resistant prostate cancer.

Niraparib Plus Abiraterone/Prednisone Maintains rPFS Benefit in HRR Gene–Altered mCRPC

February 17th 2023

The combination of niraparib, abiraterone acetate, and prednisone produced prolonged survival and delayed progression rates in patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations.

Ra-223 Displays Efficacy, Safety in mCRPC With Bone Metastases

February 17th 2023

Radium-223 demonstrated efficacy with low rates of treatment-related adverse effects and treatment discontinuation in patients with metastatic castration-resistant prostate cancer that metastasized to the bones.

Sacituzumab Govitecan Benefit Is Consistent Following CPI in Platinum-Ineligible mUC

February 17th 2023

Treatment with the anti–Trop-2 antibody-drug conjugate sacituzumab govitecan elicited an objective response rate of 32% in platinum-ineligible patients with metastatic urothelial cancer following progression on an immune checkpoint inhibitor, according to the primary analysis of TROPHY-U-01 cohort 2.

Potential Biomarkers of Response Identified for Enfortumab Vedotin in Advanced Urothelial Cancer

February 17th 2023

Tumor mutational burden and alterations in CDKN2A, CDKN2B, and MTAP were among several biomarkers that were predictive of response to enfortumab vedotin in patients with advanced urothelial carcinoma, according to findings from a retrospective analysis.

Novel Therapies Are Needed to Reduce Cost Burden With AlloHCT, GVHD

February 17th 2023

Because of an economic burden on the healthcare system occurring through the per-patient cost of allogeneic hematopoietic cell transplant, novel treatments to replace transplant and prevent graft-vs-host disease are necessary.

Ruxolitinib Induces High Responses in SR-aGVHD, Regardless of Cytopenias

February 17th 2023

The presence of cytopenias did not affect the favorable and durable responses seen with ruxolitinib vs best available therapy in patients with steroid-refractory acute graft-vs-host disease.

TURBT Plus Chemoimmunotherapy Triplet Induces Complete Responses in MIBC

February 17th 2023

Transurethral resection of bladder tumor followed by gemcitabine, cisplatin, and nivolumab led to stringent clinical complete responses in patients with muscle-invasive bladder cancer.

Ruxolitinib Provides ORR Benefit vs BAT in Early Treatment of SR-aGVHD

February 17th 2023

Early treatment with ruxolitinib led to high response rates in patients with steroid refractory acute graft-vs-host-disease, although benefits with ruxolitinib vs best available therapy were observed regardless of the timing of ruxolitinib administration.

Ruxolitinib Displays Variable Pharmacokinetics in Patients with GVHD 2 Years of Age and Under

February 17th 2023

A study did not find a correlation between the pharmacokinetics and pharmacodynamics of ruxolitinib for the treatment of patients 2 years of age and younger with graft-vs-host disease.

Orca-Q Shows Favorable GRFS in the Haplo SCT Setting Without PTCy for High-risk Hematologic Malignancies

February 17th 2023

Orca-Q when using myeloablative conditioning with only tacrolimus monotherapy in the haploidentical stem cell transplant setting had acceptable safety and resulted in encouraging outcomes for patients with high-risk hematologic malignancies.

KEYNOTE-859 Data Show 1.4-Month OS Benefit With Frontline Pembrolizumab Plus Chemo in Advanced HER2– Gastric or GEJ Cancer

February 17th 2023

The addition of pembrolizumab to chemotherapy resulted in a significant and clinically meaningful improvement in overall survival, progression-free survival, and objective response rate vs chemotherapy alone when used as first-line treatment in patients with advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma.

CD22-Directed CAR T-cell Therapy Elicits High CR Rates in LBCL After CD19 Relapse

February 17th 2023

CD22-directed CAR T-cell therapy generated high complete response rates and manageable safety in heavily pretreated patients with large B-cell lymphoma who relapsed following CD19-directed CAR T-cell therapy.

Salvage Checkpoint Inhibitors Reduce Peri-ASCT Progression in R/R Hodgkin Lymphoma

February 17th 2023

Checkpoint inhibitor–based salvage regimens significantly reduced the likelihood that patients with relapsed/refractory classic Hodgkin lymphoma undergoing transplant would need further salvage therapy vs conventional salvage regimens.

Orca-T Leads to 100% Survival Rate in Early Trial of Patients With Hematologic Malignancies and 7/8 Mismatched Donors

February 17th 2023

Orca-T produced a 100% overall survival rate in 8 patients with hematologic malignancies who received an allogeneic hematopoietic stem cell transplant with 7/8 non-permissive HLA mismatched donors.

Real-world OS Rates in aGVHD Increase in Ruxolitinib Treatment Era

February 17th 2023

Ruxolitinib induced clinically meaningful overall survival improvements by decreasing non-relapse mortality rates in patients with acute graft-vs-host-disease.

Frontline Itolizumab Elicits Durable Responses in aGVHD

February 17th 2023

First-line treatment with itolizumab produced rapid, durable responses and favorable safety in patients with acute graft-vs-host disease.

Treatment Approaches Should Remain Consistent Across Late and Classic aGVHD

February 17th 2023

Timing of severe symptom onset is the only distinct difference between late and classic acute graft-vs-host disease, and long-term outcomes were similar between the two types of disease.